Table 1.
Study demographics. Data are from patients undergoing staging for newly diagnosed disease in whom a pathology reference was applied
| Ref | Author | Year | Country | Tracer | Scanner | Study design | Recruitment | Patients, numbers | Risk group distribution | Mean number of LN removed per patient |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Budaus et al. [16] | 2016 | Germany | Ga-68-PSMA-11 | PET/CT | Retro | Non-con | 30 | High (100%) | 20 |
| 2 | Herlemann et al. [17] | 2016 | Germany | Ga-68-PSMA-11 | PET/CT | Retro | Con | 20 | Int (20%), High (80%) | 14 |
| 3 | Maurer et al. [18] | 2016 | Germany | Ga-68-PSMA-11 | PET/MR (73%), PET/CT (27%) | Retro | Con | 130 | Int (32%), High (68%) | 21a |
| 4 | Van Leeuwen et al. [19] | 2017 | Australia | Ga-68-PSMA-11 | PET/CT | Pro | Non-con | 30 | Int (10%), High (90%) | 18 |
| 5 | Uprimny et al. [20] | 2017 | Austria | Ga-68-PSMA-11 | PET/CT | Retro | Non-con | 49 | NR | NR |
| 6 | Gupta et al. [21] | 2017 | India | Ga-68-PSMA-11 | PET/CT | Retro | Non-con | 12 | High (100%) | 20 |
| 7 | Obek et al. [22] | 2017 | Turkey | Ga-68-PSMA-11 | PET/CT | Retro | Non-con | 51 | High (100%) | 20 |
| 8 | Zhang et al. [23] | 2017 | China | Ga-68-PSMA-11 | PET/CT | Retro | Con | 42 | NR | 15 |
| 9 | Park et al. [24] | 2018 | USA | Ga-68-PSMA-11 | PET/MR | Pro | Non-con | 33 | High (45%), Int (55%) | 12 |
| 10 | Van Leeuwen et al. [25] | 2018 | The Netherlands | Ga-68-PSMA-11 | PET/CT | Retro | Con | 140 | Int (21%), High (79%) | NR |
| 11 | Gorin et al. [26] | 2018 | USA | F-18-DCFPyL | PET/CT | Pro | Non-con | 25 | High (100%) | 13 |
| 12 | Cantiello et al. [27] | 2018 | Italy | Cu-64-PSMA | PET/CT | Pro | Non-con | 23 | Int (83), High (17) | 18 |
| 13 | Thalgott et al. [28] | 2018 | Germany | Ga-68-PSMA-11 | PET/MR | Retro | Con | 73 | High (100%) | 26 |
| 14 | Berger et al. [29] | 2018 | Australia | Ga-68-PSMA-11 | PET/CT | Retro | Non-con | 50 | NR (pT3, 54%; Gleason ≥8; 32%) | 12a |
| 15 | Gupta et al. [30] | 2018 | India | Ga-68-PSMA-11 | PET/CT | Retro | Con | 23 | NR (83% High based on PSA and T-stage) | 20 |
| 16 | Yaxley et al. [31] | 2019 | Australia | Ga-68-PSMA-11 | PET/CT | Retro | Con | 208 | High (59%), Int (41%( | 14 |
| 17 | Yilmaz et al. [32] | 2019 | Turkey | Ga-68-PSMA-11 | PET/CT | Retro | Con | 10 | NR | NR |
| 18 | Petersen et al. [33] | 2019 | Denmark | Ga-68-PSMA-11 | PET/MR (85%), PET/CT (15%) | Pro | Con | 20 | High (95%), Int (5%) | 29 |
aMedian
Abbreviations. Con consecutive, Int intermediate, LN lymph node, Non-con non-consecutive, NR not reported, Pro prospective, Retro retrospective